



(51) International Patent Classification:

C07J 63/00 (2006.01) *A61P 25/28* (2006.01)
A61K 31/56 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2009/041176

(22) International Filing Date:

20 April 2009 (20.04.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/046,366 18 April 2008 (18.04.2008) US
 61/111,294 4 November 2008 (04.11.2008) US

(71) Applicant (for all designated States except US): **REATA PHARMACEUTICALS, INC.** [US/US]; 2801 Gateway Dr. Ste 150, Irving, TX 75063 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JIANG, Xin** [CN/US]; 6401 Maple Ave., Apt. 5308, Dallas, TX 75235 (US). **LIU, Xiaofeng**. **GREINER, Jack**. **SZUCS, Stephen, S.** **VISNICK, Melean** [US/US]; 330 East Las Colinas Blvd., Apt. 818, Irving, TX 75039 (US).

(74) Agent: **VOGES, Mark, H.**; Fulbright & Jaworski L.L.P., 600 Congress Ave., Suite 2400, Austin, TX 78701 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES



(57) Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.